Neutral lipid storage disease
| Neutral lipid storage disease
| |
|---|---|
| Symptoms | Muscle weakness, hepatomegaly, cardiomyopathy
|
| Usual onset | Childhood or adulthood |
| Duration | Lifelong
|
| Causes | Genetic mutations |
| Risk factors | Family history |
| Diagnosis | Genetic testing, Biopsy
|
| Treatment | Symptomatic management
|
| Prognosis | Variable |
| Frequency | Rare
|
Neutral lipid storage disease (NLSD) is a rare genetic disorder characterized by the accumulation of neutral lipids in various tissues of the body. This condition can affect multiple organs, including the muscle, liver, and heart.
Classification[edit]
NLSD is classified into two main types:
- Neutral lipid storage disease with myopathy (NLSDM), also known as Chanarin-Dorfman syndrome.
- Neutral lipid storage disease with ichthyosis (NLSDI).
Signs and Symptoms[edit]
The symptoms of NLSD can vary widely depending on the type and severity of the disease. Common symptoms include:
- Muscle weakness
- Hepatomegaly (enlarged liver)
- Cardiomyopathy (heart muscle disease)
- Ichthyosis (dry, scaly skin) in NLSDI
Genetics[edit]
NLSD is caused by mutations in specific genes responsible for lipid metabolism. The most commonly affected genes are:
- ABHD5 (also known as CGI-58) in NLSDI
- PNPLA2 (also known as ATGL) in NLSDM
These mutations lead to the improper breakdown and storage of neutral lipids within cells.
Diagnosis[edit]
Diagnosis of NLSD typically involves:
- Genetic testing to identify mutations in the ABHD5 or PNPLA2 genes.
- Biopsy of affected tissues to observe lipid accumulation.
Treatment[edit]
There is currently no cure for NLSD. Treatment focuses on managing symptoms and may include:
- Physical therapy for muscle weakness
- Medications for heart and liver complications
- Skin care for ichthyosis
Prognosis[edit]
The prognosis for individuals with NLSD varies. Some may experience mild symptoms, while others may have severe complications affecting their quality of life.